{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:39:50Z","timestamp":1790786390054,"version":"4.1.0"},"reference-count":123,"publisher":"Elsevier BV","issue":"4-5","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.pcad.2017.12.004","type":"journal-article","created":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T12:32:42Z","timestamp":1514550762000},"page":"478-490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy"],"prefix":"10.1016","volume":"60","author":[{"given":"Jae Youn","family":"Moon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Franchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Rollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2017.12.004_bb0005","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/0002-8703(82)90486-0","article-title":"Results from coronary angioplasty and implications for the future","volume":"103","author":"Gruentzig","year":"1982","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2017.12.004_bb0010","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Schomig","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.12.004_bb0015","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.12.004_bb0020","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1161\/01.CIR.98.16.1597","article-title":"Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study","volume":"98","author":"Bertrand","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.12.004_bb0025","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1161\/01.CIR.98.20.2126","article-title":"Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS)","volume":"98","author":"Urban","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.12.004_bb0030","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.pcad.2017.12.004_bb0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2017.12.004_bb0040","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0045","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.12.004_bb0050","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.12.004_bb0055","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jacc.2016.03.512","volume":"68","author":"Bittl","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0060","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","volume":"102","author":"Bertrand","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.12.004_bb0065","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2017.12.004_bb0070","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1002358","article-title":"A prospective natural-history study of coronary atherosclerosis","volume":"364","author":"Stone","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.12.004_bb0075","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1253\/circj.CJ-09-0982","article-title":"Basic principles of platelet biology and clinical implications","volume":"74","author":"Angiolillo","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.pcad.2017.12.004_bb0080","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.12.004_bb0085","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2017.12.004_bb0090","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.12.004_bb0095","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2017.12.004_bb0100","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2017.12.004_bb0105","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0110","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2014.156","article-title":"Novel antiplatelet agents in acute coronary syndrome","volume":"12","author":"Franchi","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0115","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrcardio.2017.18","article-title":"Antithrombotic therapy for patients with STEMI undergoing primary PCI","volume":"14","author":"Franchi","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0120","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1161\/CIRCULATIONAHA.116.023681","article-title":"The birth, and evolution, of percutaneous coronary interventions: a conversation with Patrick Serruys, MD, PhD","volume":"134","author":"Serruys","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.12.004_bb0125","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1161\/ATVBAHA.107.144220","article-title":"Vascular responses to drug eluting stents: importance of delayed healing","volume":"27","author":"Finn","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0130","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/eurheartj\/ehs460","article-title":"Should duration of dual antiplatelet therapy depend on the type and\/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)","volume":"34","author":"Valgimigli","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2017.12.004_bb0135","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30\u202fmonths of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.12.004_bb0140","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Giustino","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0145","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.116.004395","article-title":"Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a north american perspective-2016 update","volume":"9","author":"Angiolillo","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"issue":"1","key":"10.1016\/j.pcad.2017.12.004_bb0150","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/17474086.2018.1400378","article-title":"The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts","volume":"11","author":"Moon","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0155","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/CIRCULATIONAHA.106.666800","article-title":"Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern","volume":"115","author":"Camenzind","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.12.004_bb0160","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jcin.2015.05.026","article-title":"Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy","volume":"8","author":"Kereiakes","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2017.12.004_bb0165","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jama.2015.1671","article-title":"Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial","volume":"313","author":"Kereiakes","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2017.12.004_bb0170","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1056\/NEJMoa1607991","article-title":"Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease","volume":"375","author":"Bonaa","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.12.004_bb0175","unstructured":"Varenne O, Cook S, Sideris G, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet 2002."},{"key":"10.1016\/j.pcad.2017.12.004_bb0180","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa012843","article-title":"A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization","volume":"346","author":"Morice","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.12.004_bb0185","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMoa035071","article-title":"Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery","volume":"349","author":"Moses","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.12.004_bb0190","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/01.CIR.0000086926.62288.A6","article-title":"Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions","volume":"108","author":"Colombo","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.12.004_bb0195","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1161\/CIRCULATIONAHA.105.562421","article-title":"Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial","volume":"112","author":"Sabate","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.12.004_bb0200","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(07)60314-6","article-title":"Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study","volume":"369","author":"Daemen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2017.12.004_bb0205","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa067722","article-title":"Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden","volume":"356","author":"Lagerqvist","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.12.004_bb0210","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1161\/CIRCULATIONAHA.106.180944","volume":"115","author":"Grines","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.12.004_bb0215","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.jacc.2006.10.026","article-title":"Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents","volume":"48","author":"Pfisterer","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0220","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jama.297.2.joc60179","article-title":"Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation","volume":"297","author":"Eisenstein","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2017.12.004_bb0225","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1161\/CIRCULATIONAHA.106.686048","article-title":"Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment","volume":"116","author":"Airoldi","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.12.004_bb0230","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1093\/eurheartj\/ehp275","article-title":"Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period","volume":"30","author":"Schulz","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2017.12.004_bb0235","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","article-title":"Duration of dual antiplatelet therapy after implantation of drug-eluting stents","volume":"362","author":"Park","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.12.004_bb0240","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.12.004_bb0245","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.amjcard.2005.06.056","article-title":"Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes","volume":"96","author":"Rao","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0250","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.109.878017","article-title":"Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial","volume":"121","author":"Pocock","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.12.004_bb0255","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jcin.2011.02.011","volume":"4","author":"Mehran","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2017.12.004_bb0260","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jacc.2011.07.021","article-title":"Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial","volume":"58","author":"Suh","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0265","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jacc.2015.06.1323","article-title":"Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention","volume":"66","author":"Genereux","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0270","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1161\/CIRCULATIONAHA.112.097014","article-title":"Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials","volume":"125","author":"Bangalore","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.12.004_bb0275","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/S0140-6736(12)61223-9","article-title":"Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1\u202fyear results of a randomised controlled trial","volume":"380","author":"Sabate","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2017.12.004_bb0280","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jacc.2011.06.049","article-title":"Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials","volume":"58","author":"Baber","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0285","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jcin.2012.02.014","article-title":"Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study","volume":"5","author":"Naidu","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2017.12.004_bb0290","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.114.001362","article-title":"Stent thrombosis and dual antiplatelet therapy interruption with everolimus-eluting stents: insights from the Xience V Coronary stent system trials","volume":"8","author":"Genereux","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2017.12.004_bb0295","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.jacc.2011.02.016","volume":"57","author":"Stone","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0300","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jcin.2016.04.036","article-title":"6-Month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial","volume":"9","author":"Hong","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2017.12.004_bb0305","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial","volume":"65","author":"Gilard","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0310","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jcin.2017.03.049","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: final results of the ITALIC trial (Is There a Life for DES After Discontinuation of Clopidogrel)","volume":"10","author":"Didier","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2017.12.004_bb0315","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.12.004_bb0320","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jcin.2012.12.125","article-title":"Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents","volume":"6","author":"Kandzari","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2017.12.004_bb0325","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jcin.2009.10.006","article-title":"Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial","volume":"2","author":"Kim","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2017.12.004_bb0330","doi-asserted-by":"crossref","first-page":"E871","DOI":"10.1002\/ccd.25136","article-title":"Two-week interval optical coherence tomography: imaging evidence on neointimal coverage completion after implantation of the Endeavor zotarolimus-eluting stent","volume":"82","author":"Nishinari","year":"2013","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2017.12.004_bb0335","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0340","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2017.12.004_bb0345","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jcin.2015.11.015","article-title":"Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention?: a pre-specified analysis from the ZEUS trial","volume":"9","author":"Ariotti","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2017.12.004_bb0350","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.jacc.2013.12.036","volume":"63","author":"Taniwaki","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0355","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S0140-6736(12)61336-1","article-title":"Stent thrombosis and major clinical events at 3\u202fyears after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial","volume":"380","author":"Camenzind","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2017.12.004_bb0360","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(13)62037-1","article-title":"Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial","volume":"383","author":"von Birgelen","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2017.12.004_bb0365","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.114.002230","article-title":"Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial","volume":"8","author":"Iqbal","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2017.12.004_bb0370","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/eurheartj\/ehu026","article-title":"Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12\u202fmonths following resolute zotarolimus-eluting stent implantation","volume":"35","author":"Silber","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2017.12.004_bb0375","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial","volume":"64","author":"Colombo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0380","series-title":"Kedhi E presented the result of DAPT-STEMI trial at the 29th annual Transcatheter Cardiovascular Therapeutics scientific symposium, November 1","year":"2017"},{"key":"10.1016\/j.pcad.2017.12.004_bb0385","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","article-title":"Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk","volume":"48","author":"Joner","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0390","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1161\/CIRCULATIONAHA.109.854398","article-title":"Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis","volume":"120","author":"Cook","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.12.004_bb0395","doi-asserted-by":"crossref","first-page":"f 6625","DOI":"10.1136\/bmj.f6625","article-title":"Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis","volume":"347","author":"Bangalore","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.pcad.2017.12.004_bb0400","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcin.2013.04.011","volume":"6","author":"Serruys","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2017.12.004_bb0405","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jcin.2017.02.029","volume":"10","author":"Vlachojannis","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2017.12.004_bb0410","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jcin.2017.04.019","article-title":"Dual antiplatelet therapy for 6 versus 18\u202fmonths after biodegradable polymer drug-eluting stent implantation","volume":"10","author":"Nakamura","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2017.12.004_bb0415","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4244\/EIJY15M11_07","article-title":"Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial","volume":"12","author":"Vranckx","year":"2016","journal-title":"EuroIntervention"},{"key":"10.1016\/j.pcad.2017.12.004_bb0420","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nrcardio.2017.12","article-title":"Single or dual antiplatelet therapy after PCI","volume":"14","author":"Miyazaki","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0425","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1161\/CIRCULATIONAHA.116.023952","article-title":"A critical appraisal of aspirin in secondary prevention: is less more?","volume":"134","author":"Gargiulo","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.12.004_bb0430","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2011.04453.x","article-title":"Antiplatelet effects of aspirin vary with level of P2Y(1)(2) receptor blockade supplied by either ticagrelor or prasugrel","volume":"9","author":"Kirkby","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pcad.2017.12.004_bb0435","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.114.002372","article-title":"Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial","volume":"8","author":"Kereiakes","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"issue":"10105","key":"10.1016\/j.pcad.2017.12.004_bb0440","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(17)32249-3","article-title":"Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial","volume":"390","author":"Kandzari","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2017.12.004_bb0445","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/eurheartj\/ehr196","article-title":"Capture of circulatory endothelial progenitor cells and accelerated re-endothelialization of a bio-engineered stent in human ex vivo shunt and rabbit denudation model","volume":"33","author":"Larsen","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2017.12.004_bb0450","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcin.2009.09.015","article-title":"Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization","volume":"3","author":"Nakazawa","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2017.12.004_bb0455","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.jcin.2016.02.052","article-title":"1-Year results of the REMEDEE registry: clinical outcomes after deployment of the abluminal sirolimus-coated bioengineered (combo) stent in a multicenter, prospective all-comers registry","volume":"9","author":"Woudstra","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2017.12.004_bb0460","series-title":"Suryapranata H presented 12\u202fmonth clinical outomes of REDUCE trial at the 29th annual Transcatheter Cardiovascular Therapeutics scientific symposium, November 1","year":"2017"},{"key":"10.1016\/j.pcad.2017.12.004_bb0465","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11886-017-0819-0","article-title":"Polymer-free drug-coated coronary stents in patients with stable coronary artery disease at high bleeding risk","volume":"19","author":"Panchal","year":"2017","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.pcad.2017.12.004_bb0470","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.12.004_bb0475","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ijcard.2016.07.181","article-title":"Preclinical evaluation of a novel polyphosphazene surface modified stent","volume":"222","author":"Koppara","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0480","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcin.2016.10.037","article-title":"9-Month clinical and angiographic outcomes of the COBRA polyzene-F nanocoated coronary stent system","volume":"10","author":"Cutlip","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2017.12.004_bb0485","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1253\/circj.CJ-10-1135","article-title":"Bioresorbable scaffold technologies","volume":"75","author":"Onuma","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.pcad.2017.12.004_bb0490","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.4244\/EIJY14M07_11","article-title":"Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry","volume":"10","author":"Capodanno","year":"2015","journal-title":"EuroIntervention"},{"key":"10.1016\/j.pcad.2017.12.004_bb0495","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcin.2015.09.024","article-title":"Scaffold thrombosis after percutaneous coronary intervention with ABSORB bioresorbable vascular scaffold: a systematic review and meta-analysis","volume":"9","author":"Lipinski","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2017.12.004_bb0500","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jacc.2015.08.853","article-title":"Very late scaffold thrombosis: intracoronary imaging and histopathological and spectroscopic findings","volume":"66","author":"Raber","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"33","key":"10.1016\/j.pcad.2017.12.004_bb0505","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1093\/eurheartj\/ehx155","article-title":"Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials","volume":"38","author":"Collet","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2017.12.004_bb0510","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/j.jacc.2017.10.010","article-title":"3-Year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds: the ABSORB III trial","volume":"70","author":"Kereiakes","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.pcad.2017.12.004_bb0515","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.4244\/EIJ-D-17-00873","article-title":"Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II trial)","volume":"13","author":"Chevalier","year":"2018","journal-title":"EuroIntervention"},{"key":"10.1016\/j.pcad.2017.12.004_bb0520","article-title":"Three-year outcomes with the absorb bioresorbable scaffold: individual-patient-data meta-analysis from the ABSORB randomized trials","author":"Ali","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.12.004_bb0525","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jcin.2016.12.279","article-title":"Antiplatelet therapy after implantation of bioresorbable vascular scaffolds: a review of the published data, practical recommendations, and future directions","volume":"10","author":"Capodanno","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2017.12.004_bb0530","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0535","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2017.12.004_bb0540","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12\u202fmonths of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Schulz-Schupke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2017.12.004_bb0545","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.003145","article-title":"Six versus 12\u202fmonths of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial","volume":"9","author":"Han","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2017.12.004_bb0550","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/eurheartj\/ehv712","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence","volume":"37","author":"Palmerini","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2017.12.004_bb0555","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.12.004_bb0560","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2017.12.004_bb0565","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","article-title":"Dual-antiplatelet treatment beyond 1\u202fyear after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial","volume":"384","author":"Collet","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2017.12.004_bb0570","first-page":"365","article-title":"Stopping or continuing clopidogrel 12\u202fmonths after drug-eluting stent placement: the OPTIDUAL randomized trial","volume":"37","author":"Helft","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2017.12.004_bb0575","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jacc.2015.03.003","article-title":"Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction","volume":"65","author":"Yeh","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0580","first-page":"390","article-title":"Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials","volume":"37","author":"Udell","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2017.12.004_bb0585","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.117.003563","article-title":"Bayesian analysis: a practical approach to interpret clinical trials and create clinical practice guidelines","volume":"10","author":"Bittl","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.pcad.2017.12.004_bb0590","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4244\/EIJ-D-17-00468","article-title":"State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation - past, present and future perspectives","volume":"13","author":"Gargiulo","year":"2017","journal-title":"EuroIntervention"},{"key":"10.1016\/j.pcad.2017.12.004_bb0595","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2017.12.004_bb0600","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1\u202fyear after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2017.12.004_bb0605","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","article-title":"Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS","volume":"67","author":"Baber","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2017.12.004_bb0610","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(17)30591-3","article-title":"Tailoring duration of DAPT with risk scores","volume":"389","author":"Capodanno","year":"2017","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.pcad.2017.12.004_bb0615","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062017301664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062017301664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T10:17:27Z","timestamp":1582539447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062017301664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":123,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0033062017301664"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2017.12.004","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2017.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}